KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBITDA (2016 - 2025)

Historic EBITDA for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Bristol Myers Squibb's EBITDA rose 8698.92% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 18059.14%. This contributed to the annual value of -$8.6 billion for FY2024, which is 21134.02% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's EBITDA stood at $2.2 billion, which was up 8698.92% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's EBITDA ranged from a high of $2.5 billion in Q4 2021 and a low of -$11.8 billion during Q1 2024
  • Over the past 5 years, Bristol Myers Squibb's median EBITDA value was $1.6 billion (recorded in 2021), while the average stood at $983.8 million.
  • In the last 5 years, Bristol Myers Squibb's EBITDA skyrocketed by 76938.78% in 2021 and then plummeted by 64091.95% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's EBITDA stood at $2.5 billion in 2021, then tumbled by 37.42% to $1.6 billion in 2022, then decreased by 5.06% to $1.5 billion in 2023, then plummeted by 79.89% to $302.0 million in 2024, then soared by 642.38% to $2.2 billion in 2025.
  • Its EBITDA stands at $2.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $2.3 billion for Q1 2025.